NIH Announces Closed Virtual Meetings for Scientific Grant Reviews

2026-06501 — Government-Owned Inventions; Availability for Licensing

The National Institutes of Health is offering a cool new invention—special human antibodies that can fight certain cancers and autoimmune diseases—for companies to license and develop into treatments. This means businesses can jump on this opportunity to create powerful new medicines using government-backed research. Interested parties should act soon and may need to sign agreements to get full details.

2026-06283 — Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration

The National Eye Institute plans to give Perpetual Biosciences, Inc. an exclusive license to use special PEDF peptides to treat eye diseases that cause vision loss. This means the company will have the sole right to develop and sell this promising treatment, potentially helping millions with retinal degeneration. If you want to comment or apply for a license, act fast—submissions close April 16, 2026!

2026-05957 — Center for Scientific Review; Notice of Closed Meetings

The NIH’s Center for Scientific Review is holding several closed virtual meetings in April 2026 to review and decide on important research grant applications. These meetings affect scientists seeking funding in areas like neuroscience, cancer, and liver disease. No public access is allowed to protect private info and trade secrets, and these reviews help decide where millions in research money will go.

2026-05672 — National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

The National Institute on Deafness and Other Communication Disorders is holding two closed meetings in late April and early May 2026 to review grant applications and evaluate researchers’ qualifications. These meetings affect scientists seeking funding and help ensure top-notch research gets supported. No public access means privacy is protected, and the process keeps the money flowing to the best projects on time.

2026-05673 — Center for Scientific Review; Notice of Closed Meetings

The Center for Scientific Review is holding several closed virtual meetings on April 17, 2026, to review and evaluate important grant applications in health and science fields. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.

2026-05738 — Submission for OMB Review; 30-Day Comment Request; National Institutes of Health (NIH) Loan Repayment Programs, (Office of the Director)

The NIH is asking for a 30-day public comment on extending its Loan Repayment Programs that help doctors and scientists pay off their student loans while they do important health research. This extension keeps the program running smoothly with no big changes, and comments are due by April 23, 2026. If you’re a researcher with student loans, this program could save you money while you help improve health!

Previous: 2026-05104 — Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Health Workforce Connector, OMB No. 0906-0031 Revision

HRSA is updating the Health Workforce Connector, a tool that helps connect health professionals with communities that need them. This change affects program sites and health workers involved in several federal health programs. The public can comment on these updates until April 15, 2026, with no new costs expected.

Next: 2026-05107 — Utility Scale Wind Towers From Canada, Indonesia, South Korea, and Vietnam; Determinations

The U.S. government decided to keep special taxes on big wind towers coming from Canada, Indonesia, South Korea, and Vietnam. These taxes help protect American companies from unfair competition that could hurt jobs and businesses. This decision means the taxes stay in place starting now, keeping the playing field fair and supporting U.S. industry.